A Randomized, Double-blind, Parallel Design, Single Dose, 2-arm Study Comparing the Pharmacokinetic, Safety and Immunogenicity Profiles of AVT03 and US-Xgeva® in Healthy Male Subjects
Phase: PHASE1
Conditions: This is a Phase I Study Conducted in Healthy Volunteers
Sponsor: Alvotech Swiss AG

Protocol Title: A randomized, double-blind, parallel 
design, single dose, 2-arm study 
comparing the pharmacokinetic, 
safety and immunogenicity profiles 
of AVT03 and US-Xgeva® in healthy 
male subjects 
NCT Number 
NCT05876949 
Protocol 
version and 
date 
Version 1.0, 11 January 2023